Page last updated: 2024-11-11

trilobatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trilobatin: anti-inflammatory from Lithocarpus polystachyus leaves; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

trilobatin : An aryl beta-D-glucoside that is phloretin attached to a beta-D-glucopyranosyl residue at position 4' via a glycosidic linkage. It is isolated from the leaves of the Chinese sweet tea Lithocarpus polystachyus and exhibits significant anti-hyperglycemic, anti-oxidative and anti-inflammatory properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Lithocarpusgenus[no description available]FagaceaeA plant family of the order Fagales subclass Hamamelidae, class Magnoliopsida.[MeSH]
Lithocarpus polystachyusspecies[no description available]FagaceaeA plant family of the order Fagales subclass Hamamelidae, class Magnoliopsida.[MeSH]

Cross-References

ID SourceID
PubMed CID6451798
CHEMBL ID514177
CHEBI ID145829
SCHEMBL ID1144758
MeSH IDM000606777

Synonyms (40)

Synonym
MEGXP0_002006
ACON1_000618
NCGC00168907-01
p-phlorizin
trilobatin
1-(2,6-dihydroxy-4-((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)phenyl)-3-(4-hydroxyphenyl)propan-1-one
bdbm50256748
BRD-K75748852-001-01-6
CHEMBL514177 ,
1-[2,6-dihydroxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-3-(4-hydroxyphenyl)propan-1-one
1-(4-(beta-d-glucopyranosyloxy)-2,6-dihydroxyphenyl)-3-(4-hydroxyphenyl)-1-propanone
3,5-dihydroxy-4-[3-(4-hydroxyphenyl)propanoyl]phenyl beta-d-glucopyranoside
CHEBI:145829
p-phloridzin
4192-90-9
phloretin-4'-beta-d-glucoside
phloretin-4'-beta-d-glucopyranoside
23298i791n ,
phloretin-4'-o-glucoside
1-propanone, 1-(4-(beta-d-glucopyranosyloxy)-2,6-dihydroxyphenyl)-3-(4-hydroxyphenyl)-
unii-23298i791n
S9064
phlorizin, p-
1-propanone, 1-(4-(.beta.-d-glucopyranosyloxy)-2,6-dihydroxyphenyl)-3-(4-hydroxyphenyl)-
phloretin 4'-.beta.-d-glucoside
prunin dihydrochalcone
fema no. 4674
SCHEMBL1144758
DTXSID10194681
AKOS032948098
Q3539189
HY-N4100
1-(2,6-dihydroxy-4-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)phenyl)-3-(4-hydroxyphenyl)propan-1-one
phloretin-4-o-glucoside
CCG-269084
CS-0032106
prunindihydrochalcone
AC-34712
AS-82792
Z3251695350

Research Excerpts

Overview

Trilobatin is a common type of flavonoids compounds derived from crabapple. It has wide application prospects due to its various pharmacological effects, such as anti-inflammation and anti-oxidation.

ExcerptReferenceRelevance
"Trilobatin is a flavonoid that has wide application prospects due to its various pharmacological effects, such as anti-inflammation and anti-oxidation. "( A novel electrochemical sensor based on gold nanobipyramids and poly-L-cysteine for the sensitive determination of trilobatin.
Bu, L; Chen, Z; Li, Q; Mei, X; Wang, W; Wu, M, 2023
)
2.56
"Trilobatin is a sweetener found at high concentrations in the leaves of a range of crabapple ("( Biosynthesis of the Dihydrochalcone Sweetener Trilobatin Requires
Atkinson, RG; Chagné, D; Cooney, J; Gunaseelan, K; Hamiaux, C; Li, H; Li, P; López-Girona, E; Ma, F; Tomes, S; Wang, Y; Xiao, Z; Yauk, YK; Zhang, L; Zhao, Q, 2020
)
1.54
"Trilobatin is a common type of flavonoids compounds derived from "( Trilobatin Induces Apoptosis and Attenuates Stemness Phenotype of Acquired Gefitinib Resistant Lung Cancer Cells via Suppression of NF-κB Pathway.
Li, W; Xi, Y; Yanyang, L; Yizhe, W; Zhixi, L; Zihan, X, 2022
)
3.61

Effects

ExcerptReferenceRelevance
"Trilobatin has a good potential to be developed as a small-molecule HIV-1 entry inhibitor for clinical combination therapy."( Trilobatin as an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope.
Lai, F; Li, L; Liang, T; Lin, W; Liu, S; Qiu, J; Wen, J; Yin, S; Zhang, X, 2018
)
2.64
"Trilobatin has a good potential to be developed as a small-molecule HIV-1 entry inhibitor for clinical combination therapy."( Trilobatin as an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope.
Lai, F; Li, L; Liang, T; Lin, W; Liu, S; Qiu, J; Wen, J; Yin, S; Zhang, X, 2018
)
2.64

Treatment

ExcerptReferenceRelevance
"Treatment with trilobatin (0.005-5 μM) dose-dependently inhibited the lipopolysaccharide (LPS)-induced mRNA expression and secretion of pro-inflammatory cytokines, including tumor necrosis factor α (TNFα), interleukin-1β (IL-1β) and interleukin-6 (IL-6), in RAW 264.7 macrophages."( Trilobatin attenuates the LPS-mediated inflammatory response by suppressing the NF-κB signaling pathway.
Dong, H; Fan, X; Ji, H; Liu, X; Wang, B; Zhang, Y, 2015
)
2.2
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
anti-inflammatory agentAny compound that has anti-inflammatory effects.
sweetening agentSubstance that sweeten food, beverages, medications, etc.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
aryl beta-D-glucoside
dihydrochalconesAny ketone that is 1,3-diphenylpropanone and its derivatives obtained by substitution.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 28 member 3Homo sapiens (human)Ki100.00002.10002.75003.4000AID370698
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 28 member 3Homo sapiens (human)
xenobiotic transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
pyrimidine nucleobase transportSolute carrier family 28 member 3Homo sapiens (human)
uridine transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
sodium ion transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
pyrimidine-containing compound transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
nucleoside transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
purine nucleobase transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
pyrimidine nucleoside transportSolute carrier family 28 member 3Homo sapiens (human)
purine nucleoside transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
purine nucleobase transmembrane transporter activitySolute carrier family 28 member 3Homo sapiens (human)
nucleoside:sodium symporter activitySolute carrier family 28 member 3Homo sapiens (human)
protein bindingSolute carrier family 28 member 3Homo sapiens (human)
uridine transmembrane transporter activitySolute carrier family 28 member 3Homo sapiens (human)
purine-specific nucleoside:sodium symporter activitySolute carrier family 28 member 3Homo sapiens (human)
pyrimidine- and adenosine-specific:sodium symporter activitySolute carrier family 28 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneSolute carrier family 28 member 3Homo sapiens (human)
plasma membraneSolute carrier family 28 member 3Homo sapiens (human)
brush border membraneSolute carrier family 28 member 3Homo sapiens (human)
plasma membraneSolute carrier family 28 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1420940Antioxidant activity assessed as BTH equivalent of DPPH-induced radical scavenging activity2018European journal of medicinal chemistry, Oct-05, Volume: 158Antibacterial and antioxidant activities for natural and synthetic dual-active compounds.
AID370698Binding affinity to human recombinant CNT3 expressed in pig PK15NTD cells assessed as [3H]uridine uptake by beta-scintillation counter2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors.
AID1420938Antibacterial activity against Staphylococcus aureus ATCC 6538 by agar diffusion method2018European journal of medicinal chemistry, Oct-05, Volume: 158Antibacterial and antioxidant activities for natural and synthetic dual-active compounds.
AID1420939Antibacterial activity against Escherichia coli ATCC 10536 by agar diffusion method2018European journal of medicinal chemistry, Oct-05, Volume: 158Antibacterial and antioxidant activities for natural and synthetic dual-active compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (5.00)29.6817
2010's6 (30.00)24.3611
2020's13 (65.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.00 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index5.69 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]